June 6, 2002


GlaxoSmithKline, Shire, Emory University Announce Agreement on Patent Rights

GlaxoSmithKline (NYSE: GSK), Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSE: SHQ) and Emory University announce they have signed the final agreement in settlement of global disputes over certain patent rights relating to lamivudine and emtricitabine. The agreement includes settlement of related U.S. litigation.

Under the terms of the settlement, Emory University receives a license under Shire's patents related to emtricitabine and Shire and GSK receive licenses under Emory University's patents related to lamivudine.

Triangle Pharmaceuticals is developing Coviracil® (emtricitabine) for the treatment of HIV infections under license from Emory University.

GlaxoSmithKline developed and markets Epivir® (lamivudine) for the treatment of HIV under license from Shire. Shire and GSK jointly market 3TC® (lamivudine) in Canada. GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Shire Pharmaceuticals Group plc (Shire) is a rapidly growing international specialty pharmaceutical company with a strategic focus on three therapeutic areas – central nervous system disorders (CNS), oncology and anti-infectives. Shire also has two platform technologies: advanced drug delivery and biologics. Shire's core strategy is based on research and development combined with in licensing and a focus on eight key pharmaceutical markets.

Emory University is a leading research university with one of the fastest-growing research enterprises in the nation. Emory is known for its highly recognized professional schools of medicine, public health, nursing, business, law, and theology, as well as for its advanced research facilities and an unprecedented expansion of research support in the health sciences.


UK Media
Martin Sutton, 020 8047 5502
Alan Chandler, 020 8047 5502

US Media

Nancy Pekarek, 215 751 7709
Patricia Seif, 215 751 7709
Mary Anne Rhyne, 919 483 2839

Global (outside U.S. and Canada)
Investor Relations
Clea Rosenfeld, 44 1256 894 160
Jessica Mann, 44 1256 894 280

U.S. and Canada
Investor Relations
Gordon Ngan, 1 450 978 7938
Michele Roy, 1 450 978 7876

Holly Korschun 404-727-3990
Ron Sauder 404-727-3366

Return to June Index

For more general information on The Robert W. Woodruff Health Sciences Center
call Health Sciences Communication's Office at 404-727-5686,
or send e-mail to hsnews@emory.edu

Copyright © Emory University, 2001. All Rights Reserved.